EDSA
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Edesa Biotech, Inc. (EDSA) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D+). The rating has held at C- for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C+ (2.5) | D+ (1.8) | D+ (1.8) | D+ (1.6) | C+ (2.6) | C- (2.1) |
| 2026-11-04 | C+ (2.5) | C- (1.9) | D+ (1.8) | D+ (1.8) | C+ (2.7) | C- (2.1) |
| 2026-10-28 | C+ (2.5) | C- (1.9) | D+ (1.8) | D (1.4) | C+ (2.7) | C- (2.1) |
| 2026-10-21 | C+ (2.5) | D+ (1.8) | D+ (1.8) | D+ (1.8) | C+ (2.6) | C- (2.1) |
| 2026-10-14 | C+ (2.5) | D+ (1.8) | D+ (1.8) | C- (2.0) | C+ (2.6) | C- (2.1) |